Latest Ai Driven Drug Discovery News

Pathkey.AI has upgraded its TrialKey platform to include drug-level molecular and pharmacokinetic features, enhancing clinical trial predictions and opening doors to AI-driven drug discovery.

Algorae Pharmaceuticals has advanced its AI-driven drug discovery platform into preclinical validation through a strategic collaboration with the Peter MacCallum Cancer Centre, while progressing its therapeutic pipeline and commercial leadership.

Opyl Limited unveils a bold strategic pivot to enhance its AI-driven drug discovery platform, leveraging a vast proprietary dataset and leadership upgrades to redefine clinical trial innovation.

Algorae Pharmaceuticals has secured a significant A$318,771 R&D tax incentive rebate from the Australian Taxation Office, providing a non-dilutive cash injection to advance its AI-driven drug discovery programs.

Algorae Pharmaceuticals reports significant progress in its AI-driven drug discovery platform, unveiling 24 novel oncology targets and appointing a seasoned Chief Commercial Officer to bolster market readiness.